phase III clinical study
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
The Phase III trial explored two combinations, Opdivo plus Yervoy and Opdivo plus chemo, in esophageal cancer and stratified patients based on PD-L1 expression.
Sanofi Partners With Research Groups to Study Amcenestrant in ER-Positive Breast Cancer
The global trial will compare the activity of the selective estrogen receptor degrader amcenestrant against tamoxifen in patients who cannot receive adjuvant aromatase inhibitors.
Innovent Biologics Begins Phase III Trial of First-Line Pemazyre for Bile Duct Cancer in China
The firm, which has rights to Incyte's agent in the country, is evaluating the drug versus chemo for cholangiocarcinoma patients harboring FGFR2 fusions.
CHMP Recommends Merck's Keytruda Plus Chemo for Certain Esophageal, Gastroesophageal Cancers
The EMA committee recommended approval for pembrolizumab plus chemo as first-line treatment for patients whose tumors express a PD-L1 CPS of 10 or more.